skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

Download Your Whitepaper Today

In response to recent data fraud findings, the China Food and Drug Administration (CFDA) has ruled that its approved generic drugs be retested. For pharmaceutical companies, investigators, and CROs there is more pressure than ever to improve drug quality and reporting— or be blacklisted.

Can you trust BE drug trial results from China, and is it advisable for pharma companies to plan their next study there?

Get answers to these and other burning questions when you download this whitepaper from Citeline. Leveraging real-time data intelligence from Trialtrove, the industry’s most comprehensive, accurate and up-to-date source of pharmaceutical clinical trials data, this paper dives deep into the history, current landscape and future of bioequivalence studies in China including:

  • The major players sponsoring BE trials now, and the drugs they are testing
  • Disease patient segmentation and protocol design
  • Targeted investigator details
  • Provinces with the most and least activity

お問い合わせ&レポートストア

専任スタッフによるデモンストレーションを兼ねたサービスの詳しいご説明、または無料トライアルを常時受け付けています。ご希望の場合は下記のフォームよりお気軽にお申し込みください。

*一部のサービスでは無料トライアルをご利用になれません。

ご質問等ございましたらお気軽にご連絡下さい。

日本(平日:9時~18時)
電話:+81 (0)3 6273 4260
Email:inquiry.jp@informa.com

オンラインショップのレポートストアでは、医療用医薬品の市場調査・分析レポートを常時1000本以上販売しています。レポート1本単位で購入でき、オンラインでご提供いたします。

お探しの情報が見つからない場合はお問い合わせ先までお気軽にご連絡ください。